Ethiopia Health News API

{
    "totalArticles": 5912,
    "articles": [
        {
            "id": "8e87d4946cebabcbf8ed7a3c6b736019",
            "title": "Tech-funded Project Intercept Aims to Strike Down Cold and Flu",
            "description": "Backed by $500M investment, Project Intercept will fund therapies to protect against multiple respiratory pathogens like cold and flu.",
            "content": "Backed by approximately $500 million in investment from Big Tech, the Intercept initiative will back broad-spectrum preventatives and air-cleaning technologies to reduce the global health burden of respiratory infections.\nRT’s Three Key Takeaways:\nBr... [3411 chars]",
            "url": "https://respiratory-therapy.com/disorders-diseases/infectious-diseases/other-infections/tech-funded-project-intercept-aims-to-strike-down-cold-and-flu/",
            "image": "https://respiratory-therapy.com/wp-content/uploads/2023/02/nih-influenzaB-52393278373_d1a35e37ab_o.jpg",
            "publishedAt": "2026-06-25T19:35:31Z",
            "lang": "en",
            "source": {
                "id": "d87d3d309067482ef2e97a6fefd35377",
                "name": "respiratory-therapy.com",
                "url": "https://respiratory-therapy.com"
            }
        },
        {
            "id": "bc76087a929e66a0eac3334322d442bf",
            "title": "Antibody therapy keeps some with CSU swelling-free for months",
            "description": "Antibody therapy barzolvolimab kept up to 64% of CSU patients in a trial free of angioedema seven months after their last dose.",
            "content": "The investigational therapy barzolvolimab rapidly reduced angioedema in people with chronic spontaneous urticaria (CSU) in a Phase 2 trial, and many remained free of swelling months after treatment ended.\nAt the trial’s final assessment, conducted at... [5667 chars]",
            "url": "https://angioedemanews.com/news/antibody-therapy-keeps-csu-swelling-free-months/",
            "image": "https://angioedemanews.com/wp-content/uploads/2024/06/Conference.png",
            "publishedAt": "2026-06-25T19:24:30Z",
            "lang": "en",
            "source": {
                "id": "fc242f014fe52dce92d3e3786caa6c3e",
                "name": "Angioedema News",
                "url": "https://angioedemanews.com"
            }
        },
        {
            "id": "a8d45727d9032baef91375030f86ea3a",
            "title": "‘Paradigm-shifting’ treatment for pediatric diabetes cleared by FDA",
            "description": "Yale’s Kevan Herold was the senior investigator on a clinical trial which showed that the drug teplizumab — recently approved for pediatric patients with Stage 3 Type 1 diabetes — delays the progression of the disease.",
            "content": "For more than 30 years, Yale endocrinologist Kevan Herold has been researching treatments for Type 1 diabetes (T1D). For just as long, he’s been the principal investigator for multiple clinical trials involving a drug called teplizumab, also known as... [3973 chars]",
            "url": "https://news.yale.edu/2026/06/25/paradigm-shifting-treatment-pediatric-diabetes-cleared-fda",
            "image": "https://news.yale.edu/sites/default/files/styles/opengraph_image/public/2026-06/YN_Kevan-Herold.jpg?h=4e409016&itok=3dd1vTsj",
            "publishedAt": "2026-06-25T19:23:22Z",
            "lang": "en",
            "source": {
                "id": "7cdb9bbca2a7b9a9605408133f0172b7",
                "name": "YaleNews",
                "url": "https://news.yale.edu"
            }
        }
    ]
}